-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
China Resources Medical Holdings Company Limited's (HKG:1515) Stock Price Dropped 6.7% Last Week; Individual Investors Would Not Be Happy
China Resources Medical Holdings Company Limited's (HKG:1515) Stock Price Dropped 6.7% Last Week; Individual Investors Would Not Be Happy
A look at the shareholders of China Resources Medical Holdings Company Limited (HKG:1515) can tell us which group is most powerful. With 50% stake, individual investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
And following last week's 6.7% decline in share price, individual investors suffered the most losses.
Let's take a closer look to see what the different types of shareholders can tell us about China Resources Medical Holdings.
View our latest analysis for China Resources Medical Holdings
SEHK:1515 Ownership Breakdown September 20th 2022What Does The Institutional Ownership Tell Us About China Resources Medical Holdings?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
China Resources Medical Holdings already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at China Resources Medical Holdings' earnings history below. Of course, the future is what really matters.
SEHK:1515 Earnings and Revenue Growth September 20th 2022Hedge funds don't have many shares in China Resources Medical Holdings. The company's largest shareholder is China Resources Company Limited, with ownership of 37%. Meanwhile, the second and third largest shareholders, hold 6.0% and 1.7%, of the shares outstanding, respectively.
After doing some more digging, we found that the top 18 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of China Resources Medical Holdings
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our most recent data indicates that insiders own less than 1% of China Resources Medical Holdings Company Limited. However, it's possible that insiders might have an indirect interest through a more complex structure. It has a market capitalization of just HK$5.6b, and the board has only HK$8.0m worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling.
General Public Ownership
With a 50% ownership, the general public, mostly comprising of individual investors, have some degree of sway over China Resources Medical Holdings. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Company Ownership
It seems that Private Companies own 37%, of the China Resources Medical Holdings stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 2 warning signs for China Resources Medical Holdings that you should be aware of before investing here.
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
看看華潤醫療控股有限公司(HKG:1515)的股東就知道哪個集團最有權勢。個人投資者持有50%的股份,即擁有公司的最高股份。換句話説,該集團將從他們對公司的投資中獲得最大(或損失最大)。
繼上週股價下跌6.7%之後,散户投資者遭受的損失最大。
讓我們仔細看看不同類型的股東能告訴我們關於華潤醫療控股的情況。
查看我們對華潤醫療控股的最新分析
聯交所:1515 2022年9月20日所有權分類關於華潤醫療控股,機構持股告訴了我們什麼?
機構投資者通常將自己的回報與經常跟蹤的指數的回報進行比較。因此,他們通常確實會考慮收購被納入相關基準指數的較大公司。
華潤醫療控股已有機構在股份登記處登記。事實上,他們在該公司擁有可觀的股份。這可以表明該公司在投資界具有一定的公信力。然而,最好警惕依賴機構投資者帶來的所謂驗證。他們也一樣,有時也會犯錯。如果多家機構同時改變對一隻股票的看法,你可能會看到股價迅速下跌。因此,下面華潤醫療控股的盈利歷史值得一看。當然,未來才是真正重要的。
聯交所:2022年9月20日盈利及收入增長1515對衝基金在華潤醫療控股的股份並不多。該公司最大股東為華潤股份有限公司,持股37%。與此同時,第二大和第三大股東分別持有6.0%和1.7%的流通股。
在進一步挖掘後,我們發現前18名股東合計持有公司50%的股份,這表明沒有單一股東對公司擁有重大控制權。
研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。有很多分析師在追蹤這隻股票,所以他們的預測可能也是值得的。
華潤醫療控股的內部人所有權
不同國家對內部人的定義可能略有不同,但董事會成員總是算數的。公司管理層對董事會負責,董事會應代表股東的利益。值得注意的是,有時最高層管理人員本身也是董事會成員。
大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟。然而,在某些情況下,太多的權力集中在這個羣體中。
我們的最新數據顯示,內部人士持有華潤醫療控股有限公司不到1%的股份。然而,內部人士可能會通過更復雜的結構擁有間接利益。該公司市值僅為56億港元,董事會僅有價值80萬港元的自有股票。許多小公司的投資者更希望看到董事會加大投資。你可以點擊這裏,看看這些內部人士是一直在買入還是賣出。
一般公有制
擁有50%股權的普通公眾,主要由個人投資者組成,對華潤醫療控股有一定程度的影響力。這種規模的所有權雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。
私營公司所有權
看起來,民營企業持有華潤醫療控股37%的股份。私營公司可能是關聯方。有時,內部人士通過持有一傢俬人公司來對上市公司感興趣,而不是以個人身份。雖然很難得出任何大致的中風結論,但值得注意的是,這是一個值得進一步研究的領域。
接下來的步驟:
雖然考慮擁有一家公司的不同集團是很值得的,但還有其他更重要的因素。例如,我們發現華潤醫療控股的2個警告信號在這裏投資之前你應該意識到這一點。
最終未來是最重要的。您可以訪問此免費分析師對該公司的預測報告。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧